Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80.
Article
CAS
Google Scholar
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37.
Article
CAS
Google Scholar
Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.
CAS
Google Scholar
Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121:4854–60.
Article
CAS
Google Scholar
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.
Article
Google Scholar
do Pazo C, Nawaz K, Webster RM. The oncology market for antibody–drug conjugates. Nat Rev Drug Discov. 2021;20:583–4.
Article
CAS
Google Scholar
Arlotta KJ, Owen SC. Antibody and antibody derivatives as cancer therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11: e1556.
Article
Google Scholar
Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions—improving antibodies for cancer treatment. Antibodies. 2020;9(4):64.
Article
Google Scholar
Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. The platelet Fc receptor. FcγRIIa Immunol Rev. 2015;268:241–52.
Article
CAS
Google Scholar
Uppal H, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123–33.
Article
CAS
Google Scholar
Pegram MD, et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther. 2021;20:1442–53.
Article
CAS
Google Scholar
Deonarain MP. Miniaturised ’antibody’-drug conjugates for solid tumours? Drug Discov Today Technol. 2018;30:47–53.
Article
Google Scholar
Deonarain MP, Yahioglu G. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov. 2021;16:613–24.
Article
CAS
Google Scholar
Deonarain MP, et al. Small-format drug conjugates: a viable alternative to ADCs for solid tumours? Antibodies. 2018;7(2):16.
Article
CAS
Google Scholar
Rypáček F, Drobník J, Chmelař V, Kálal J. The renal excretion and retention of macromolecules. Pflugers Arch. 1982;392:211–7.
Article
Google Scholar
Pyzik M, et al. The neonatal Fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540.
Article
CAS
Google Scholar
Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit.’ Nat Rev Drug Discov. 2018;17:197–223.
Article
CAS
Google Scholar
Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46.
Article
CAS
Google Scholar
Herrera AF, et al. Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-cell non-hodgkin lymphoma: phase 1 dose-escalation study. Clin Cancer Res. 2022;28:1294–301.
Article
CAS
Google Scholar
Zhou Q. Site-specific antibody conjugation for ADC and beyond. Biomedicines. 2017;5:E64.
Article
Google Scholar
Duivelshof BL, et al. Glycan-mediated technology for obtaining homogeneous site-specific conjugated antibody-drug conjugates: synthesis and analytical characterization by using complementary middle-up LC/HRMS analysis. Anal Chem. 2020;92:8170–7.
Article
CAS
Google Scholar
Zhang L, et al. A simple and efficient method to generate dual site-specific conjugation ADCs with cysteine residue and an unnatural amino acid. Bioconjugate Chem. 2021;32:1094–104.
Article
CAS
Google Scholar
Hussain AF, et al. Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches. Pharmaceuticals. 2021;14(4):343.
Article
CAS
Google Scholar
Dai Z, et al. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci Adv. 2020;6(23):eaba6752.
Article
CAS
Google Scholar
Puthenveetil S, et al. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate. PLoS ONE. 2017;12: e0178452.
Article
Google Scholar
Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H. Impact of payload hydrophobicity on the stability of antibody-drug conjugates. Mol Pharm. 2018;15:2656–64.
Article
CAS
Google Scholar
Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11:99–109.
Article
CAS
Google Scholar
Lyon RP, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–5.
Article
CAS
Google Scholar
Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.
Article
CAS
Google Scholar
Simmons JK, Burke PJ, Cochran JH, Pittman PG, Lyon RP. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol Appl Pharmacol. 2020;392: 114932.
Article
CAS
Google Scholar
Li Q, et al. PEG linker improves antitumor efficacy and safety of affibody-based drug conjugates. Int J Mol Sci. 2021;22:1540.
Article
CAS
Google Scholar
Shao S, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett. 2018;28:1363–70.
Article
CAS
Google Scholar
Burke PJ, et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol Cancer Ther. 2017;16:116–23.
Article
CAS
Google Scholar
Sonzini S, et al. Improved physical stability of an antibody-drug conjugate using host-guest chemistry. Bioconjug Chem. 2020;31:123–9.
Article
CAS
Google Scholar
Viricel W, et al. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chem Sci. 2019;10:4048–53.
Article
CAS
Google Scholar
Conilh L, et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals. 2021;14(3):247.
Article
CAS
Google Scholar
Dovgan I, et al. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency. Sci Rep. 2020;10:7691.
Article
CAS
Google Scholar
Yurkovetskiy AV, et al. A polymer-based antibody-Vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res. 2015;75:3365–72.
Article
CAS
Google Scholar
Okajima D, et al. Datopotamab Deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329–40.
Article
CAS
Google Scholar
Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389–97.
Article
CAS
Google Scholar
Anderl J, Faulstich H, Hechler T, Kulke M. Antibody–drug conjugate payloads. In: Ducry L editor. Antibody-Drug Conjugates, 2013. pp. 51–70. https://doi.org/10.1007/978-1-62703-541-5_4.
Widdison WC, Chari RVJ. Factors involved in the design of cytotoxic payloads for antibody–drug conjugates. In: Phillips GL editor Antibody-drug conjugates and immunotoxins: from pre-clinical development to therapeutic applications. Springer; 2013. pp. 93–115. https://doi.org/10.1007/978-1-4614-5456-4_6.
Mantaj J, Jackson PJM, Rahman KM, Thurston DE. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl. 2017;56:462–88.
Article
CAS
Google Scholar
Yaghoubi S, et al. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020;235:31–64.
Article
CAS
Google Scholar
Saber H, Simpson N, Ricks TK, Leighton JK. An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. Regul Toxicol Pharmacol. 2019;107: 104429.
Article
CAS
Google Scholar
Hartley JA. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2021;21:931–43.
Article
CAS
Google Scholar
Lee A. Loncastuximab tesirine: first approval. Drugs. 2021;81:1229–33.
Article
CAS
Google Scholar
Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80:501–8.
Article
CAS
Google Scholar
Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80:1019–25.
Article
CAS
Google Scholar
Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:20.
Article
CAS
Google Scholar
Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann Oncol. 2017;28:3083–91.
Article
CAS
Google Scholar
Ogitani Y, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108.
Article
CAS
Google Scholar
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512.
Article
Google Scholar
Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802.
Article
CAS
Google Scholar
Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33.
Article
CAS
Google Scholar
Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2013;8:82–95.
Article
CAS
Google Scholar
Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994;86:836–42.
Article
CAS
Google Scholar
Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Investig Drugs. 2004;13:269–84.
Article
CAS
Google Scholar
Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148: 104398.
Article
CAS
Google Scholar
Thomas A, Pommier Y. Targeting topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019;25:6581–9.
Article
CAS
Google Scholar
Takegawa N, et al. DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–9.
Article
CAS
Google Scholar
Abou-Alfa GK, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–300.
Article
CAS
Google Scholar
Ogitani Y, et al. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett. 2016;26:5069–72.
Article
CAS
Google Scholar
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.
Article
CAS
Google Scholar
Takegawa N, et al. DS-8201a, a new HER2-targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–9.
Article
CAS
Google Scholar
Iwata TN, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494–503.
Article
CAS
Google Scholar
Nagai Y, Oitate M, Shiozawa H, Ando O. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019;49:1086–96.
Article
CAS
Google Scholar
Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21.
Article
CAS
Google Scholar
Shitara K, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.
Article
CAS
Google Scholar
Research, C. for D. E. and. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. FDA. 2022.
Cortés J, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.
Article
Google Scholar
Li BT, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med. 2022;386:241–51.
Article
CAS
Google Scholar
Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22:779–89.
Article
CAS
Google Scholar
Commissioner, O. of the. FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer. 2022.
Liu H, et al. Abstract P196: novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity. Mol Cancer Ther. 2021;20:P196.
Article
Google Scholar
AACR Annual Meeting 2022-The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity. https://cattendee.abstractsonline.com/meeting/10517/Presentation/12222.
AACR Annual Meeting 2022 - PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse carcinoma models. https://cattendee.abstractsonline.com/meeting/10517/Presentation/12260.
AACR Annual Meeting 2022 - PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma. https://cattendee.abstractsonline.com/meeting/10517/Presentation/12232.
Li W, et al. Synthesis and evaluation of camptothecin antibody-drug conjugates. ACS Med Chem Lett. 2019;10:1386–92.
Article
CAS
Google Scholar
AACR Annual Meeting 2022-Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead. https://cattendee.abstractsonline.com/meeting/10517/Presentation/12224.
Gupta E, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–5.
CAS
Google Scholar
Haaz MC, Rivory L, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 1998;58:468–72.
CAS
Google Scholar
Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80:1019–25.
Article
CAS
Google Scholar
Moon S-J, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916–26.
Article
CAS
Google Scholar
Govindan SV, Cardillo TM, Moon S-J, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052–61.
Article
CAS
Google Scholar
Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015;12:1836–47.
Article
CAS
Google Scholar
Cardillo TM, et al. IMMU-140, a novel SN-38 antibody-drug conjugate targeting HLA-DR, mediates dual cytotoxic effects in hematologic cancers and malignant melanoma. Mol Cancer Ther. 2018;17:150–60.
Article
CAS
Google Scholar
Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012;11:224–34.
Article
CAS
Google Scholar
Govindan SV, et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther. 2013;12:968–78.
Article
CAS
Google Scholar
Yao Y, et al. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. J Control Release. 2015;220:5–17.
Article
CAS
Google Scholar
Yasunaga M, Manabe S, Tarin D, Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci. 2013;104:231–7.
Article
CAS
Google Scholar
Yasunaga M, Manabe S, Tarin D, Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjugate Chem. 2011;22:1776–83.
Article
CAS
Google Scholar
Yasunaga M, Manabe S, Matsumura Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci Rep. 2017;7:10735.
Article
Google Scholar
Burke PJ, et al. Design, synthesis, and biological evaluation of antibody−drug conjugates comprised of potent camptothecin analogues. Bioconjugate Chem. 2009;20:1242–50.
Article
CAS
Google Scholar
Gupta N, et al. Development of a facile antibody–drug conjugate platform for increased stability and homogeneity. Chem Sci. 2017;8:2387–95.
Article
CAS
Google Scholar
Lyski RD, et al. Development of novel antibody-camptothecin conjugates. Mol Cancer Ther. 2021;20:329–39.
Article
CAS
Google Scholar
Ryan M, et al. SGN-CD30C, an investigational CD30-Directed camptothecin antibody-drug conjugate (ADC), Shows strong anti tumor activity and superior tolerability in preclinical studies. Blood. 2020;136:41–2.
Article
Google Scholar
Lyski R, et al. Abstract 2885: discovery of a tripeptide-based camptothecin drug-linker for antibody-drug conjugates with potent antitumor activity and a broad therapeutic window. Can Res. 2020;80:2885.
Article
Google Scholar
Kummar S, et al. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78:73–81.
Article
CAS
Google Scholar
Lv P-C, et al. Design, synthesis, and biological evaluation of potential prodrugs related to the experimental anticancer agent indotecan (LMP400). J Med Chem. 2016;59:4890–9.
Article
CAS
Google Scholar
Kurtzberg LS, et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011;17:2777–87.
Article
CAS
Google Scholar
Sooryakumar D, Dexheimer TS, Teicher BA, Pommier Y. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011;10:1490–9.
Article
CAS
Google Scholar
Marzi L, et al. Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol Cancer Ther. 2018;17:1694–704.
Article
CAS
Google Scholar
Our Pipeline | Gibson Oncology. https://gibsononcology.com/our-pipeline/.
Elias DJ, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma1. Can Res. 1990;50:4154–9.
CAS
Google Scholar
Saleh MN, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18:2282–92.
Article
CAS
Google Scholar
Tolcher AW, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17:478–84.
Article
CAS
Google Scholar
Sapra P, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11:5257–64.
Article
CAS
Google Scholar
Luong A, Issarapanichkit T, Kong SD, Fong R, Yang J. pH-Sensitive, N-ethoxybenzylimidazole (NEBI) bifunctional crosslinkers enable triggered release of therapeutics from drug delivery carriers. Org Biomol Chem. 2010;8:5105–9.
Article
CAS
Google Scholar
Stefan N, et al. Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, Site-specific Conjugation. Mol Cancer Ther. 2017;16:879–92.
Article
CAS
Google Scholar
Junttila MR, et al. Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med. 2015;7(314):314ra186.
Article
Google Scholar
Tolcher AW, et al. NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—a phase 1/2 clinical trial. JCO. 2021. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS1108.
Article
Google Scholar
Sadilkova LK, et al. Abstract 1204: SO-N102, a novel CLDN182-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels. Cancer Res. 2021;81:1204.
Article
Google Scholar
Yu S-F, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res. 2015;21:3298–306.
Article
CAS
Google Scholar
D’Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16.
Article
Google Scholar
Dal Corso A, Gébleux R, Murer P, Soltermann A, Neri D. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J Control Release. 2017;264:211–8.
Article
Google Scholar
Holte D, et al. Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg Med Chem Lett. 2020;30: 127640.
Article
CAS
Google Scholar
AACR Annual Meeting 2022-Development and characterization of an epiregulin antibody-drug conjugate for targeting colorectal cancer cell plasticity. https://cattendee.abstractsonline.com/meeting/10517/Presentation/16961.
Nilchan N, et al. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation. Antib Ther. 2019;2:71–8.
CAS
Google Scholar
Kato Y, et al. A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate. J Med Chem. 1984;27:1602–7.
Article
CAS
Google Scholar
Lavie E, et al. Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue. Cancer Immunol Immunother. 2005. https://doi.org/10.1007/BF01744941.
Article
Google Scholar
Pietersz GA, Smyth MJ, McKenzie IF. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res. 1988;48:926–31.
CAS
Google Scholar
Rowland AJ, Pietersz GA, McKenzie IF. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol Immunother. 1993;37:195–202.
Article
CAS
Google Scholar
Ghanemi M, et al. Specific targeting of HER2-positive head and neck squamous cell carcinoma line HN5 by idarubicin-ZHER2 affibody conjugate. Curr Cancer Drug Targets. 2019;19:65–73.
Article
CAS
Google Scholar
Laham-Karam N, Pinto GP, Poso A, Kokkonen P. Transcription and translation inhibitors in cancer treatment. Front Chem. 2020;8:276.
Article
CAS
Google Scholar
Lindell TJ, Weinberg F, Morris PW, Roeder RG, Rutter WJ. Specific inhibition of nuclear RNA polymerase II by α-amanitin. Science. 1970;170:447–9.
Article
CAS
Google Scholar
Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91:140–9.
Article
CAS
Google Scholar
Garcia J, et al. Amanita phalloides poisoning: mechanisms of toxicity and treatment. Food Chem Toxicol. 2015;86:41–55.
Article
CAS
Google Scholar
Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;30:85–9.
Article
Google Scholar
Barbanti-Brodano G, Fiume L. Selective killing of macrophages by amanitin-albumin conjugates. Nat New Biol. 1973;243:281–3.
Article
CAS
Google Scholar
Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006;55:1337–47.
Article
CAS
Google Scholar
Hechler T, Kulke M, Mueller C, Pahl A, Anderl J. Abstract 664: amanitin-based antibody-drug conjugates targeting the prostate-specific membrane antigen. Can Res. 2014;74:664.
Article
Google Scholar
Gallo F, et al. Enhancing the pharmacokinetics and antitumor activity of an α-amanitin-based small-molecule drug conjugate via conjugation with an Fc domain. J Med Chem. 2021;64:4117–29.
Article
CAS
Google Scholar
Davis MT, Preston JF. A conjugate of alpha-amanitin and monoclonal immunoglobulin G to Thy 1.2 antigen is selectively toxic to T lymphoma cells. Science. 1981;213:1385–8.
Article
CAS
Google Scholar
Figueroa-Vazquez V, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20:367–78.
Article
CAS
Google Scholar
AACR Annual Meeting 2022-Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models. https://cattendee.abstractsonline.com/meeting/10517/Presentation/12238.
Moldenhauer G, et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012;104:622–34.
Article
CAS
Google Scholar
Kulke M, et al. Abstract 735: SAR of amanitin and optimization of linker-amanitin derivatives for solid tumors. Can Res. 2018;78:735.
Article
Google Scholar
Świderska KW, Szlachcic A, Opaliński Ł, Zakrzewska M, Otlewski J. FGF2 dual warhead conjugate with monomethyl auristatin E and α-amanitin displays a cytotoxic effect towards cancer cells overproducing FGF receptor 1. Int J Mol Sci. 2018;19:2098.
Article
Google Scholar
Barbanti-Brodano G, Derenzini M, Fiume L. Toxic action of a phalloidin-albumin conjugate on cells with a high protein uptake. Nature. 1974;248:63–5.
Article
CAS
Google Scholar
Hinman, L. M. & Yarranton, G. Chapter 25. New approaches to non-immunogenic monoclonal antibody cancer therapies. In: Bristol JA editor Annual Reports in Medicinal Chemistry, 1993. vol. 28, pp. 237–246.
Nielsen C, Casteel M, Didier A, Dietrich R, Märtlbauer E. Trichothecene-induced cytotoxicity on human cell lines. Mycotoxin Res. 2009;25:77–84.
Article
CAS
Google Scholar
Liu X, Bushnell DA, Kornberg RD. RNA polymerase II transcription: structure and mechanism. Biochim Biophys Acta. 2013;1829:2–8.
Article
CAS
Google Scholar
Noel P, et al. Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. 2019;40:327–41.
Article
CAS
Google Scholar
Hayashi M, et al. Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing mRNA synthesis. Cancers. 2019;11:E1138.
Article
Google Scholar
Zhang K, et al. Cetuximab-triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II. Mol Ther Oncolytics. 2020;18:304–16.
Article
CAS
Google Scholar
Wei D, et al. Site-specific construction of triptolide-based antibody-drug conjugates. Bioorg Med Chem. 2021;51: 116497.
Article
CAS
Google Scholar
Hideshima T, Richardson P, Anderson K. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011. https://doi.org/10.1158/1535-7163.MCT-11-0433.
Article
Google Scholar
McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.
Article
CAS
Google Scholar
Cini E, et al. Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation †Electronic supplementary information (ESI) available: experimental procedures, biological activity data, NMR spectra for characterisation. Chem Sci. 2018;9:6490–6. https://doi.org/10.1039/c7sc05266a.
Article
CAS
Google Scholar
Milazzo FM, et al. ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1. Front Oncol. 2020;9:1534.
Article
Google Scholar
Cianferotti C, et al. Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition. Chem Commun. 2021;57:867–70.
Article
CAS
Google Scholar
Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.
Article
CAS
Google Scholar
Tse C, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–8.
Article
CAS
Google Scholar
Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.
Article
CAS
Google Scholar
Trudel S, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007;109:5430–8.
Article
CAS
Google Scholar
Baggstrom MQ, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1757–60.
Article
Google Scholar
Hu Y, et al. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett. 2018;423:47–59.
Article
CAS
Google Scholar
Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013;9:390–7.
Article
CAS
Google Scholar
Zhang H, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943–51.
Article
CAS
Google Scholar
Deeks DE. Venetoclax: first global approval. Drugs. 2016;76:979–87.
Article
CAS
Google Scholar
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res. 2020;152: 104609.
Article
CAS
Google Scholar
Jaiswal N, Akhtar J, Singh SP, Badruddeen, Ahsan F. An overview on genistein and its various formulations. Drug Res. 2019;69:305–13.
Article
CAS
Google Scholar
Messinger Y, et al. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin Cancer Res. 1998;4:165–70.
CAS
Google Scholar
Ek O, et al. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. Leuk Lymphoma. 1998;30:389–94.
Article
CAS
Google Scholar
Chen C-L, et al. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in patients with B-lineage lymphoid malignancies. J Clin Pharmacol. 1999;39:1248–55.
Article
CAS
Google Scholar
Uckun FM, et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res. 1999;5:3906–13.
CAS
Google Scholar
Uckun FM, et al. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res. 1998;4:1125–34.
CAS
Google Scholar
Gentile MS, et al. Targeting colon cancer cells with genistein-17.1A immunoconjugate. Int J Oncol. 2003;22:955–9.
CAS
Google Scholar
Zhou D, et al. Novel PIKK inhibitor antibody-drug conjugates: synthesis and anti-tumor activity. Bioorg Med Chem Lett. 2019;29:943–7.
Article
CAS
Google Scholar
Wang RE, et al. An immunosuppressive antibody-drug conjugate. J Am Chem Soc. 2015;137:3229–32.
Article
CAS
Google Scholar
Chao W-T, et al. Abstract 3729: developing cetuximab-staurosporine conjugate as the therapeutic medicine in KRAS/BRAF mutated colon cancer cells. Can Res. 2018;78:3729.
Article
Google Scholar
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers. 2021;13:2695.
Article
CAS
Google Scholar
Wang Y, et al. Small-molecule modulators of toll-like receptors. Acc Chem Res. 2020. https://doi.org/10.1021/acs.accounts.9b00631.
Article
Google Scholar
Janku F, et al. 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-SITC2020.0378.
Article
Google Scholar
Ackerman SE, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18–33.
Article
CAS
Google Scholar
Ackerman SE, et al. Abstract 1559: TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation leading to enhanced effector function and anti-tumor immunity in pre-clinical models. Can Res. 2019;79:1559.
Article
Google Scholar
LeBlanc H, et al. 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2020-SITC2020.0605.
Article
Google Scholar
Mallet W, et al. 784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors. J Immunother Cancer. 2021. https://doi.org/10.1136/jitc-2021-SITC2021.784.
Article
Google Scholar
AACR Annual Meeting 2022-The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming. https://cattendee.abstractsonline.com/meeting/10517/Presentation/16947.
AACR Annual Meeting 2022-PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models. https://cattendee.abstractsonline.com/meeting/10517/Presentation/16962.
Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. JCO. 2020;38:3110–3110.
Article
Google Scholar
Comeau MR, et al. Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTACTMtherapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity. Can Res. 2020;80:4537.
Article
Google Scholar
Gadd AJR, Greco F, Cobb AJA, Edwards AD. Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity. Bioconjugate Chem. 2015;26:1743–52.
Article
CAS
Google Scholar
Ackerman SE, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18–33.
Article
CAS
Google Scholar
He L, et al. Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64:15716–26.
Article
CAS
Google Scholar
AACR Annual Meeting 2022-Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate. https://cattendee.abstractsonline.com/meeting/10517/Presentation/21768.
AACR Annual Meeting 2022-First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors. https://cattendee.abstractsonline.com/meeting/10517/Presentation/20324.
Banerjee M, et al. Abstract LB-061: CRD5500: a versatile small molecule STING agonist amenable to bioconjugation as an ADC. Cancer Research. 2019;79:LB-061.
Article
Google Scholar
AACR Annual Meeting 2022-XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab. https://cattendee.abstractsonline.com/meeting/10517/Presentation/17073.
Duvall JR, et al. Abstract 1738: XMT-2056, a well-tolerated, immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity. Can Res. 2021;81:1738.
Article
Google Scholar
AACR Annual Meeting 2022 - Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells. https://cattendee.abstractsonline.com/meeting/10517/Presentation/14046.
Scott AM, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810–7.
Article
CAS
Google Scholar
Park H-K, et al. Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1. Exp Mol Med. 2020;52:79–91.
Article
CAS
Google Scholar
Mandler R, Dadachova E, Brechbiel JK, Waldmann TA, Brechbiel MW. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate. Bioorg Med Chem Lett. 2000;10:1025–8.
Article
CAS
Google Scholar
Mandler R, Kobayashi H, Davis MY, Waldmann TA, Brechbiel MW. Modifications in synthesis strategy improve the yield and efficacy of geldanamycin−herceptin immunoconjugates. Bioconjugate Chem. 2002;13:786–91.
Article
CAS
Google Scholar
Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 2004;64:1460–7.
Article
CAS
Google Scholar
Burke PJ, et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorg Med Chem Lett. 2009;19:2650–3.
Article
CAS
Google Scholar
Lim KS, Lee DY, Han S, Bull DA, Won Y-W. Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor. Biomaterials. 2021;273: 120817.
Article
CAS
Google Scholar
Effenberger KA, Urabe VK, Jurica MS. Modulating splicing with small molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA. 2017;8(2):e1381.
Article
Google Scholar
Lee SC-W, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22:976–86.
Article
CAS
Google Scholar
Puthenveetil S, et al. Natural product splicing inhibitors: a new class of antibody-drug conjugate (ADC) payloads. Bioconjug Chem. 2016;27:1880–8.
Article
CAS
Google Scholar
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20:1735–40.
Article
CAS
Google Scholar
Jeffrey SC, De Brabander J, Miyamoto J, Senter PD. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents. ACS Med Chem Lett. 2010;1:277–80.
Article
CAS
Google Scholar
Almaliti J, et al. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. Eur J Med Chem. 2019;161:416–32.
Article
CAS
Google Scholar
Stanton BZ, Chory EJ, Crabtree GR. Chemically induced proximity in biology and medicine. Science. 2018;359:eaao5902.
Article
Google Scholar
Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022. https://doi.org/10.1038/s41573-021-00371-6.
Article
Google Scholar
Dragovich PS. Degrader-antibody conjugates. Chem Soc Rev. 2022. https://doi.org/10.1039/d2cs00141a.
Article
Google Scholar
Pillow TH, et al. Antibody Conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem. 2020;15:17–25.
Article
CAS
Google Scholar
Dragovich PS, et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties. J Med Chem. 2021;64:2534–75.
Article
CAS
Google Scholar
Dragovich PS, et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J Med Chem. 2021;64:2576–607.
Article
CAS
Google Scholar
Maneiro M, et al. Antibody–PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem Biol. 2020;15:1306–12.
Article
CAS
Google Scholar
Chuang SH et al. Conjugués Anticorps-Protac. 2019
Dragovich PS, et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg Med Chem Lett. 2020;30: 126907.
Article
CAS
Google Scholar
AACR Annual Meeting 2022-ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer. https://cattendee.abstractsonline.com/meeting/10517/Presentation/15093.
Neumann CS, et al. Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates. Mol Cancer Ther. 2018;17:2633–42.
Article
CAS
Google Scholar
Karpov AS, et al. Nicotinamide phosphoribosyltransferase inhibitor as a novel payload for antibody-drug conjugates. ACS Med Chem Lett. 2018;9:838–42.
Article
CAS
Google Scholar
El-Nassan HB. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem. 2013;62:614–31.
Article
CAS
Google Scholar
Lerchen H-G, et al. Antibody-drug conjugates with pyrrole-based KSP inhibitors as the payload class. Angew Chem Int Ed Engl. 2018;57:15243–7.
Article
CAS
Google Scholar
Lerchen H-G, et al. Tailored linker chemistries for the efficient and selective activation of ADCs with KSPi payloads. Bioconjugate Chem. 2020;31:1893–8.
Article
CAS
Google Scholar
Karpov AS, et al. Discovery of potent and selective antibody-drug conjugates with Eg5 inhibitors through linker and payload optimization. ACS Med Chem Lett. 2019;10:1674–9.
Article
CAS
Google Scholar
Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14:20.
Article
CAS
Google Scholar
Su Z, et al. Antibody–drug conjugates: recent advances in linker chemistry. Acta Pharmaceutica Sinica B. 2021;11:3889–907.
Article
CAS
Google Scholar
Trapani D, Curigliano G. Accelerating progress in early triple-negative breast cancer: a viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. The Breast. 2021. https://doi.org/10.1016/j.breast.2021.12.012.
Article
Google Scholar
Xiao D, et al. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics. 2021;11:2550–63.
Article
CAS
Google Scholar
Joubert N, Denevault-Sabourin C, Bryden F, Viaud-Massuard M-C. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. Eur J Med Chem. 2017;142:393–415.
Article
CAS
Google Scholar
Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736–42.
Article
CAS
Google Scholar
Szot C, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927–43.
Article
Google Scholar
Love EA, et al. Developing an antibody-drug conjugate approach to selective inhibition of an extracellular protein. ChemBioChem. 2019;20:754–8.
Article
CAS
Google Scholar
Testa C. et al. First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. J Enzyme Inhib Med Chem. https://doi.org/10.1016/j.breast.2021.12.012
Theocharopoulos C, Lialios P-P, Samarkos M, Gogas H, Ziogas DC. Antibody-drug conjugates: functional principles and applications in oncology and beyond. Vaccines. 2021;9:1111.
Article
CAS
Google Scholar
Dragovich PS. Antibody-drug conjugates for immunology. J Med Chem. 2022;65:4496–9.
Article
CAS
Google Scholar
Hobson AD, et al. Design and development of glucocorticoid receptor modulators as immunology antibody-drug conjugate payloads. J Med Chem. 2022;65:4500–33.
Article
CAS
Google Scholar
Dragovich PS. Antibody-drug conjugates for immunology. J Med Chem. 2022;65:4496–9.
Article
CAS
Google Scholar
Lehar SM, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323–8.
Article
CAS
Google Scholar
Lim RKV, et al. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjug Chem. 2015;26:2216–22.
Article
CAS
Google Scholar
Trudel S, et al. Targeting B-Cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma: a dose-escalation and expansion phase 1 trial (BMA117159). Lancet Oncol. 2018;19:1641–53.
Article
CAS
Google Scholar
Lonial S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21.
Article
CAS
Google Scholar
Swain SM, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106: 102378.
Article
CAS
Google Scholar